Douglas Sipp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Douglas Sipp has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- Jeremy Sugarman
Berman Institute of Bioethics and Department of Medicine, Johns Hopkins University, Baltimore, USA
8 shared publications - John Edward Joshua Rasko
Artificial Intelligence Cross Disciplinary Research Institute and Faculty of medicine, Macau University of Science and Technology, Macau, China
5 shared publications - Ian Kerridge
The University of Sydney, Sydney, Australia
4 shared publications Jonathan Kimmelman
STREAM research group, Biomedical Ethics Unit, McGill University, Montreal, Quebec H3A 1X1, Canada
4 shared publications- Leigh Turner
Department of Health, Society, and Behavior, University of California Irvine Irvine, CA 92697
4 shared publications - Megan Munsie
Murdoch Children's Research Institute, Melbourne, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia
4 shared publications
Latest Publications
- 15 September 2020
- Published by The Company of Biologists in Development
- Vol. 147 (18)
New trends in cellular therapy
Regenerative therapies, including both gene and cellular therapies, aim to induce regeneration of cells, tissues and organs and restore their functions. In this short Spotlight, we summarize the latest advances in cellular therapies using pluripotent stem cells (PSCs), highlighting the current status of clinical trials using induced (i)PSC-derived cells. We also discuss the different cellular products that might be used in clinical studies, and consider safety issues and other challenges in iPSC-based cell therapy.
- 15 September 2020
- Published by The Company of Biologists in Development
- Vol. 147 (18)
New trends in cellular therapy
Regenerative therapies, including both gene and cellular therapies, aim to induce regeneration of cells, tissues and organs and restore their functions. In this short Spotlight, we summarize the latest advances in cellular therapies using pluripotent stem cells (PSCs), highlighting the current status of clinical trials using induced (i)PSC-derived cells. We also discuss the different cellular products that might be used in clinical studies, and consider safety issues and other challenges in iPSC-based cell therapy.
- 1 September 2019
- Published by Elsevier in Cell Stem Cell
- Vol. 25 (3) , 304-305
Stem Cell Businesses and Right to Try Laws
- 1 September 2019
- Published by Elsevier in Cell Stem Cell
- Vol. 25 (3) , 304-305
Stem Cell Businesses and Right to Try Laws
- 16 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 365 (6454) , 644-646
Downgrading of regulation in regenerative medicine
What should be a firm commitment to product efficacy is threatened by economic competition
- 16 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 365 (6454) , 644-646
Downgrading of regulation in regenerative medicine
What should be a firm commitment to product efficacy is threatened by economic competition
- 19 February 2019
- Published by SAGE Publications in Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine
- Vol. 23 (4) , 436-457
The politics of evidence in online illness narratives: An analysis of crowdfunding for purported stem cell treatments
This article addresses the growing trend of crowdfunding for unproven stem cell-based treatments. Our analysis uses quantitative and qualitative data collected from two popular fundraising sites to examine how these sites are used to fund purported stem cell ‘treatments’ or ‘therapies’. In addition to mapping the use and success of these online campaigns by people with different health conditions in different locations, we consider the breakthrough restitution story as a key narrative that campaign organisers use to solicit donations. We argue that crowdfunding is a rapidly growing digital space where ‘truths’ about experimental treatments are constituted and a politics of evidence is unfolding. These developments are to the potential financial benefit of crowdfunding platforms and businesses offering unproven stem cell-based interventions, and to the potential detriment of patients and their supporters.
- 19 February 2019
- Published by SAGE Publications in Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine
- Vol. 23 (4) , 436-457
The politics of evidence in online illness narratives: An analysis of crowdfunding for purported stem cell treatments
This article addresses the growing trend of crowdfunding for unproven stem cell-based treatments. Our analysis uses quantitative and qualitative data collected from two popular fundraising sites to examine how these sites are used to fund purported stem cell ‘treatments’ or ‘therapies’. In addition to mapping the use and success of these online campaigns by people with different health conditions in different locations, we consider the breakthrough restitution story as a key narrative that campaign organisers use to solicit donations. We argue that crowdfunding is a rapidly growing digital space where ‘truths’ about experimental treatments are constituted and a politics of evidence is unfolding. These developments are to the potential financial benefit of crowdfunding platforms and businesses offering unproven stem cell-based interventions, and to the potential detriment of patients and their supporters.
- Open Access
- 1 November 2018
- Published by Elsevier in Stem Cell Reports
- Vol. 11 (5) , 1021-1025
Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report
- 1 November 2018
- Published by Elsevier in Stem Cell Reports
- Vol. 11 (5) , 1021-1025
Open AccessTackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report
- 8 October 2018
- Published by Wiley in ISBT Science Series
- Vol. 14 (1) , 45-48
Stem cell mismarketing: Implications for the transfusion community
A global industry engaged in the direct‐to‐consumer marketing of unproven uses of putative stem cells has emerged over the past 15 years. Despite strong criticism from professional societies and the scientific media, and numerous documented cases of severe adverse events, including tumorigenesis, blindness and death, the industry has continued to grow. Attempts to understand this expansion have focused variously on the valorization of patient autonomy and hope, the manipulative use of social media and celebrity endorsements, the ‘disruptive innovation’ business model and the lack of clear regulations governing cell‐based interventions in many countries. In this article, I will discuss another possible contributing factor: the regulatory exceptions afforded blood and blood products under the relevant federal code in the United States, which has served as an influential policy model in other countries. I will also scan the horizon for new directions the stem cell mismarketing industry may now be exploring, with direct implications for transfusion medicine.
- 8 October 2018
- Published by Wiley in ISBT Science Series
- Vol. 14 (1) , 45-48
Stem cell mismarketing: Implications for the transfusion community
A global industry engaged in the direct‐to‐consumer marketing of unproven uses of putative stem cells has emerged over the past 15 years. Despite strong criticism from professional societies and the scientific media, and numerous documented cases of severe adverse events, including tumorigenesis, blindness and death, the industry has continued to grow. Attempts to understand this expansion have focused variously on the valorization of patient autonomy and hope, the manipulative use of social media and celebrity endorsements, the ‘disruptive innovation’ business model and the lack of clear regulations governing cell‐based interventions in many countries. In this article, I will discuss another possible contributing factor: the regulatory exceptions afforded blood and blood products under the relevant federal code in the United States, which has served as an influential policy model in other countries. I will also scan the horizon for new directions the stem cell mismarketing industry may now be exploring, with direct implications for transfusion medicine.
- 26 September 2018
- Published by Springer Nature in Nature
- Vol. 561 (7724) , 455-457
Clear up this stem-cell mess
- 26 September 2018
- Published by Springer Nature in Nature
- Vol. 561 (7724) , 455-457
Clear up this stem-cell mess
- 21 August 2018
- Published by H1 Connect
Faculty Opinions recommendation of Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.
In this brief review, Bauer et al. provide a summary analysis of serious adverse events (AEs) following putative stem cell treatments reported in the scientific and mass media to date. They identify a total of 35 AEs, including arrhythmias, tumor lesions, meningitis, pulmonary embolism, blindness, and death following injections or infusions of purported hematopoietic and fetal neural stem cells, "mesenchymal stem/stromal cells" (a contestable designation), as well as olfactory ensheathing cells. Intravenous and intrathecal injections were associated with particularly high incidence of severe AEs. This work represents the first attempt to comprehensively list harms, including death, suffered by patients receiving putative stem cell transplants. The safety issues documented in this report are particularly striking given the increased adoption of stem cell transplants by unorthodox health practitioners and the failure of many websites marketing such treatments to disclose the attendant risks {1}.
- 21 August 2018
- Published by H1 Connect
Faculty Opinions recommendation of Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.
In this brief review, Bauer et al. provide a summary analysis of serious adverse events (AEs) following putative stem cell treatments reported in the scientific and mass media to date. They identify a total of 35 AEs, including arrhythmias, tumor lesions, meningitis, pulmonary embolism, blindness, and death following injections or infusions of purported hematopoietic and fetal neural stem cells, "mesenchymal stem/stromal cells" (a contestable designation), as well as olfactory ensheathing cells. Intravenous and intrathecal injections were associated with particularly high incidence of severe AEs. This work represents the first attempt to comprehensively list harms, including death, suffered by patients receiving putative stem cell transplants. The safety issues documented in this report are particularly striking given the increased adoption of stem cell transplants by unorthodox health practitioners and the failure of many websites marketing such treatments to disclose the attendant risks {1}.
- Open Access
- 22 June 2018
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 360 (6395) , 1275
Emerging stem cell ethics
It has been 20 years since the first derivation of human embryonic stem cells. That milestone marked the start of a scientific and public fascination with stem cells, not just for their biological properties but also for their potentially transformative medical uses. The next two decades of stem cell research animated an array of bioethical debates, from the destruction of embryos to derive stem cells to the creation of human-animal hybrids. Ethical tensions related to stem cell clinical translation and regulatory policy are now center stage and a topic of global discussion this week at the International Society for Stem Cell Research (ISSCR) annual meeting in Melbourne, Australia. Care must be taken to ensure that entry of stem cell–based products into the medical marketplace does not come at too high a human or monetary price.
- 22 June 2018
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 360 (6395) , 1275
Open AccessEmerging stem cell ethics
It has been 20 years since the first derivation of human embryonic stem cells. That milestone marked the start of a scientific and public fascination with stem cells, not just for their biological properties but also for their potentially transformative medical uses. The next two decades of stem cell research animated an array of bioethical debates, from the destruction of embryos to derive stem cells to the creation of human-animal hybrids. Ethical tensions related to stem cell clinical translation and regulatory policy are now center stage and a topic of global discussion this week at the International Society for Stem Cell Research (ISSCR) annual meeting in Melbourne, Australia. Care must be taken to ensure that entry of stem cell–based products into the medical marketplace does not come at too high a human or monetary price.
- 2 June 2018
- Published by H1 Connect
Faculty Opinions recommendation of Conditional Approvals for Autologous Stem Cell-Based Interventions: Conflicting norms and institutional legitimacy.
In this article, Lee and Lysaght provide an overview of "conditional approval" pathways available for human cell and tissue products (or "regenerative medicine products") in the EU and Japan. These accelerated market access pathways have been introduced in these regions to hasten approvals of cell biologics, and may have contributed to the introduction of the related RMAT accelerated approval scheme in the US. Lee and Lysgaht highlight the physical risks and systemic financial burden of such systems when they are not implemented in deft and well-reasoned manner. They further speculate on the broader impact of such schemes in potentially undermining the authority of marketing approval by competent authorities relying on more rigorous evidence from adequate and well-designed pre-market studies. This is an issue of some importance to the field, and to medical regulation in general, as calls for new conditional pathways are beginning to make inroads into markets for small-molecule drugs as well (e.g., the Japanese Ministry of Health recently called for a conditional approval pathway for drugs subject to certain preconditions).
- 2 June 2018
- Published by H1 Connect
Faculty Opinions recommendation of Conditional Approvals for Autologous Stem Cell-Based Interventions: Conflicting norms and institutional legitimacy.
In this article, Lee and Lysaght provide an overview of "conditional approval" pathways available for human cell and tissue products (or "regenerative medicine products") in the EU and Japan. These accelerated market access pathways have been introduced in these regions to hasten approvals of cell biologics, and may have contributed to the introduction of the related RMAT accelerated approval scheme in the US. Lee and Lysgaht highlight the physical risks and systemic financial burden of such systems when they are not implemented in deft and well-reasoned manner. They further speculate on the broader impact of such schemes in potentially undermining the authority of marketing approval by competent authorities relying on more rigorous evidence from adequate and well-designed pre-market studies. This is an issue of some importance to the field, and to medical regulation in general, as calls for new conditional pathways are beginning to make inroads into markets for small-molecule drugs as well (e.g., the Japanese Ministry of Health recently called for a conditional approval pathway for drugs subject to certain preconditions).